Navigation Links
Should Cholesterol Drugs Be Used By Those Without High Cholesterol?
Date:4/2/2010

Some experts say statins help healthier people, but others worry about risks

FRIDAY, April 2 (HealthDay News) -- When the U.S. Food and Drug Administration in February approved the use of the cholesterol-lowering statin drug Crestor for some people with normal cholesterol levels, cardiologist Dr. Steven E. Nissen cheered the decision.

"You have to go with the scientific evidence," said Nissen, who is chairman of cardiovascular medicine at the Cleveland Clinic. "A clinical trial was done and there was a substantial reduction in morbidity and mortality in people treated with this drug."

But Dr. Mark A. Hlatky, a professor of health research and policy and medicine at Stanford University, has expressed doubts about the FDA move. He worries that more people will rely on a pill rather than diet and exercise to cut their heart risk, and also points to studies linking statins such as Crestor to muscle troubles and even diabetes.

"I haven't seen anything that changes my mind about that," Hlatky said.

So, will millions of healthy Americans soon join the millions of less-than-healthy people who already take these blockbuster drugs?

The FDA's Feb. 9 approval of expanded use of rosuvastatin (Crestor) was based on results of the JUPITER study, which involved more than 18,000 people and was financed by the drug's maker, AstraZeneca. People in the trial who took the drug for an average of 1.9 years had a 44 percent lower risk of heart attack, stroke and other cardiovascular problems compared to those who took a placebo -- results so outstanding that the trial was cut short. Based on JUPITER, an FDA advisory committee voted 12 to 4 in December to approve widened use of the drug.

The people in the trial included men over 50 and women over 60 with normal or near-normal cholesterol levels. However, these individuals did have high levels of C-reactive protein, a marker of inflammation that has also been linked to cardiovascular problems. They also had at least one other heart risk factor, such as obesity or high blood pressure.

For that specific group, Crestor makes sense, Nissen said. "Over a five-year period of time, you prevent one death or minor stroke for every 25 people treated," he noted.

Whether or not others with normal cholesterol should take Crestor or another statin remains unclear. "Not everyone with normal cholesterol should be treated," Nissen said. "You should give it to people with a high enough risk."

And he added that the results applied only to Crestor. Other popular statins include Lipitor, Pravachol and Zocor, as well as some generic versions.

Those statins might not produce the same benefits, Nissen said. "Statins differ from each other in terms of potency," Nissen said. Crestor, which is available only in a more expensive brand-name form, is toward the top of the list in terms of potency, he noted, while generic drugs such as simvastatin (Zocor) and pravastatin (Pravachol) have much less powerful effects.

"For patients who need a lot of cholesterol reduction, I use the most powerful drug," Nissen said. "If I can get a patient there with a generic drug, of course I use a generic drug."

But Hlatky has his doubts about the advisability of widening statins' reach. He said he's reluctant to have people at cardiovascular risk pop a pill rather than change the lifestyle factors that put them in trouble in the first place.

"My view has always been that you start with the basics and do the simple things first before you go to drugs," Hlatky said. "Lots of people are not doing the sensible things. They're not eating the right diet, they're not exercising, they're still smoking. Most of the people in the JUPITER trial were smack in the middle of that group."

So Hlatky says he might still prescribe a statin for someone in that group, "but I would have an informed conversation about the long-term risks and benefits and what you need to do to reduce the risks."

"It is so much easier to prescribe a drug than to change behavior, and that is my worry," Hlatky said. "We're heading down that road. Cardiovascular risk prevention is moving in the wrong direction."

He's also worried about exposing more people to the rare but still possible side effects that come with statins. The drugs can cause myalgia -- severe muscle pain -- and a recent study published in the British journal The Lancet found a 9 percent increase in diabetes incidence among people taking statins.

But Nissen believes the benefits of expanded use of Crestor outweigh possible risks. The study that found an increased incidence of diabetes did not find that it was accompanied by any increase in cardiovascular problems and deaths, he noted.

"The is one example where the FDA got it exactly right," Nissen said.

More information

There's more about cholesterol control at the American Heart Association.



SOURCES: Steven E. Nissen, M.D., chairman, cardiovascular medicine, Cleveland Clinic, Cleveland; Mark A. Hlatky, M.D., professor, health research policy and medicine, Stanford University, Stanford, Calif.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Pentagon and Congress should act quickly to end gay military ban, APA says
2. Repeat of Fire Tragedy in Chicago High-Rise Should Have Been Prevented
3. Women should be allowed to eat, drink during labor: Queens University researcher
4. Transparency Should Not Be a Luxury; It Is a Matter of Life and Death: What Purchasers and Consumers Can Do
5. SIRIUS XM to Broadcast Doctor Radio Reports: Kids and Video Games - What You Should Know Before You Buy
6. Emotions should be taken seriously
7. Going to the gym shouldnt be a workout for your eardrums
8. Should HPV Test Replace the Pap Smear?
9. Shoulder Repair Technique Borrows From Cadavers
10. Patients With Pacemakers Should Avoid MRI Scans
11. Who Should Deliver Your Baby? New Tool Helps Expectant Parents Choose Their Health Care Provider
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology: